An innovative approach for the characterization of the isoforms of a monoclonal antibody product
- 4 November 2011
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 3 (6) , 505-512
Abstract
Protein biopharmaceuticals, such as monoclonal antibodies (mAbs) are widely used for the prevention and treatment of various diseases. The complex and lengthy upstream and downstream production methods of the antibodies make them susceptible to physical and chemical modifications. Several IgG1 immunoglobulins are used as medical agents for the treatment of colon, breast, and head and neck cancers, and at least four to eight isoforms exist in the products. The regulatory agencies understand the complex nature of the antibody molecules and allow the manufactures to set their own specifications for lot release, provided the safety and efficacy of the products are established in animal models prior to clinical trials. During the manufacture of a mAb product, we observed lot-to-lot variability in the isoform content and, although the variability is within the set specifications for lot release, made attempts to gain mechanistic insight by isolating and characterizing the individual isoforms. Matrix-assisted laser desorption/ionization (MALDI) and liquid chromatography (LC)/mass spectrometry (MS)/MS analyses of the isolated isoforms indicate that this variability is caused by sialic acid content, as well as truncation of C-terminal lysine of the individual isoforms. Sialidase and carboxypeptidase treatment of the product confirm the observations made by MALDI and LC/MS/MS.Keywords
This publication has 40 references indexed in Scilit:
- Engineering host cell lines to reduce terminal sialylation of secreted antibodiesmAbs, 2010
- Characterization of Antibody Charge Heterogeneity Resolved by Preparative Immobilized pH GradientsAnalytical Chemistry, 2010
- Current and Emerging Treatment Strategies for Cutaneous T-cell LymphomaDrugs, 2010
- Evidence for Trisulfide Bonds in a Recombinant Variant of a Human IgG2 Monoclonal AntibodyAnalytical Chemistry, 2009
- Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionalityMolecular Immunology, 2007
- Development and regulation of monoclonal antibody products: Challenges and opportunitiesCancer and Metastasis Reviews, 2005
- Characterization of a Novel Modification to Monoclonal Antibodies: Thioether Cross-link of Heavy and Light ChainsAnalytical Chemistry, 2005
- The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular CytotoxicityJournal of Biological Chemistry, 2003
- Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1997)Journal of Immunotherapy, 1997
- Glycosylation of Antibody Molecules: Structural and Functional Significance1996